Difference between revisions of "Team:EPFL"

Line 37: Line 37:
 
                     <h3 class="heading h3">What is CAPOEIRA ?</h3>
 
                     <h3 class="heading h3">What is CAPOEIRA ?</h3>
 
                     <div class="text-center mt-4">
 
                     <div class="text-center mt-4">
                         <p class="lead lh-180">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of its therapy. Immunooncological approaches to treatment are becoming ever more important, with immunotherapy harnessing the immune system's existing weapons in the fight against malignancy. The project that the 2018 EPFL iGEM team presents is focused on developing new techniques for treating melanoma, the deadliest form of skin cancer, by providing a set of tools to identify promising targets, rapidly manufacture an array of corresponding vaccines, and detect potential cancer relapse all on a personalized basis. The project is exhaustive and can be divided into the following parts:</p>
+
                         <p class="lead lh-180">While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to retaliate!</p>
 
                     </div>
 
                     </div>
 
                 </div>
 
                 </div>

Revision as of 17:46, 27 September 2018

iGEM EPFL 2018

CAPOEIRA

Cancer Personalized Encapsulin Immunotherapy and Relapse Assay

What is CAPOEIRA ?

While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to retaliate!

Detection

Detection of cancer patient specific tumor mutations and neoantigens

Vaccine

Expression of the neoantigens and the adjuvant using encapsulin

Immune response

Maturation of dendritic cells and T-cells

Follow up

Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA